Treatment allocation designates the regulated process by which trial participants are assigned to a treatment condition or a study arm defined in the protocol. It encompasses the practical implementation of a predefined allocation rule from the decision on eligibility to the documented assignment. Allocation can be randomized or non-randomized; its method must fit the study design and be traceably documented.<\/p>\n
The protocol describes the study arms, the allocation method and the measures to reduce bias. In randomized trials, the allocation sequence is generated with a chance element. It can be performed, for example, simply, in blocks or stratified according to predefined factors. Stratification can reduce the probability of relevant imbalances between groups, for instance regarding prognostically important baseline characteristics or in multicenter trials.<\/p>\n
The method must not merely be described technically. It must consider the clinical question, the sample size, the number of arms and the subsequent analysis. If factors are used in the randomization, the primary analysis should appropriately reflect this restriction of the randomization. According to ICH E6(R3), the retention of randomization codes and procedures for a potentially necessary code break also belong in the planning documents.<\/p>\n
The allocation only follows after verification of the eligibility criteria defined in the protocol and after the required informed consent and study processes. Trial supply systems can document the assignment and control the dispensing of the investigational medication intended for the allocated arm. Crucial is a verifiable chain between participant identification, time of allocation, study arm, dispensed treatment and all subsequent changes.<\/p>\n
Deviations are not only logistical errors. An incorrect or delayed allocation, an unintentional change or an impermissible unblinding can influence the comparability of the groups and the integrity of the trial. Such incidents must be assessed, documented and, if necessary, considered in the analysis and report. The actual exposure and the randomized assignment must be recorded separately in this context.<\/p>\n
Treatment allocation is the umbrella term for the process of assignment to a treatment condition. Randomization is a special allocation method: it deliberately employs a chance element to assign participants to different groups and to reduce bias. Thus, not every treatment allocation is randomized; for example, single-arm or certain non-randomized trials can use other assignment rules.<\/p>\n
Randomization also does not define the study arm itself. The study arm contains the planned treatment condition, while randomization governs the assignment to it. For the evaluation, the randomized allocation is frequently the basis of the primary comparison. At the same time, actual treatment, deviations and therapy discontinuations must be recorded, because they can be relevant for the estimand and supplementary analyses.<\/p>\n
The allocation data are central source data for the definition of the analysis population and the assessment of comparability. They must align with the protocol, the data from investigational sites and the system data for medicinal product supply. In the event of missing or contradictory information, a traceable data clarification is required. Changes to the analysis sets after unblinding are justifiable only under exceptional circumstances and must be documented.<\/p>\n
In confirmatory trials, the statistical analysis plan should specify how the groups are assigned for the primary and supplementary analyses, how stratification factors are accounted for and how deviations are handled. Allocation is thus not merely an administrative step, but a prerequisite for an unbiased comparison of the treatment conditions defined in the study objective.<\/p>\n
Blinding describes which persons do not know the allocated treatment, such as participants, investigational staff, endpoint assessors or analysts. It is not a method for generating the allocation sequence. Its purpose is to reduce distortions due to expectations or knowledge of the treatment during conduct, assessment and analysis.<\/p>\n
Concealed allocation, on the other hand, protects the allocation process from the next assignment being predictable before the decision on inclusion. It thus concerns the protection against selection bias prior to or during the assignment. A trial can be randomized but not blinded; it can employ blinded endpoint assessments even though treatment and conduct are open. The terms must not be equated.<\/p>\n
A robust treatment allocation protects the comparability of the groups and makes the trial conduct verifiable. Critical are clear roles, access controls for codes, validated processes and timely clarification of deviations. Inspections specifically review whether the documented allocations correspond to the protocol and whether unblindings or errors were controlled, justified and their impact assessed.<\/p>\n
Full-service CROs such as Mediconomics support with the specification of randomization and allocation processes in the protocol, with the coordination of allocation and medicinal product systems as well as with the training of investigational sites. They align monitoring, data management and biostatistics, verify the consistency of the allocation data and document deviations and code breaks for analysis and clinical study report.<\/p>\n
Is treatment allocation always randomization?<\/strong><\/p>\n No. Randomization is an important, but not the only method of assignment. Non-randomized designs can use other predefined allocation rules.<\/p>\n Why is concealed allocation important?<\/strong><\/p>\n It prevents an upcoming allocation from influencing the decision on inclusion or treatment and thus reduces selection bias.<\/p>\n Can an open-label trial have a reliable allocation?<\/strong><\/p>\n Yes. A trial can be conducted open-label and still use a proper randomization and concealed allocation. Blinding is an additional protection.<\/p>\n Treatment allocation designates the regulated process by which trial participants are assigned to a treatment condition or a study arm defined in the protocol. It encompasses the practical implementation of a predefined allocation rule from the decision on eligibility to the documented assignment. Allocation can be randomized or non-randomized; its method must fit the study […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6604","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6604\/revisions"}],"predecessor-version":[{"id":7507,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6604\/revisions\/7507"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6604"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n